Rhumbline Advisers reduced its stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 2.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 77,294 shares of the biopharmaceutical company’s stock after selling 1,687 shares during the period. Rhumbline Advisers owned 0.10% of Inovio Pharmaceuticals worth $606,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Inovio Pharmaceuticals by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after acquiring an additional 226,861 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new stake in shares of Inovio Pharmaceuticals during the second quarter worth $1,411,000. Credit Suisse AG boosted its position in Inovio Pharmaceuticals by 108.6% during the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock valued at $879,000 after purchasing an additional 69,068 shares during the last quarter. Geode Capital Management LLC boosted its position in Inovio Pharmaceuticals by 12.5% during the first quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock valued at $3,708,000 after purchasing an additional 62,045 shares during the last quarter. Finally, Private Capital Advisors Inc. acquired a new stake in Inovio Pharmaceuticals during the second quarter valued at $274,000. Institutional investors and hedge funds own 24.83% of the company’s stock.

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) opened at 6.34 on Monday. The firm’s market cap is $572.04 million. Inovio Pharmaceuticals, Inc. has a 12 month low of $5.28 and a 12 month high of $9.86. The firm has a 50 day moving average price of $5.73 and a 200-day moving average price of $6.65.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.08. The business had revenue of $20.41 million during the quarter, compared to analysts’ expectations of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The firm’s revenue was up 229.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.26) earnings per share. On average, analysts predict that Inovio Pharmaceuticals, Inc. will post ($0.92) EPS for the current fiscal year.

A number of research analysts have commented on INO shares. Piper Jaffray Companies upgraded Inovio Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $14.00 target price on the stock in a research note on Thursday, June 8th. HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 27th. Maxim Group reaffirmed a “buy” rating and set a $12.00 price target on shares of Inovio Pharmaceuticals in a research note on Tuesday, September 12th. Zacks Investment Research raised Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a research note on Tuesday, July 11th. Finally, BidaskClub upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, September 9th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $19.80.

TRADEMARK VIOLATION WARNING: “Inovio Pharmaceuticals, Inc. (INO) Shares Sold by Rhumbline Advisers” was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/inovio-pharmaceuticals-inc-ino-shares-sold-by-rhumbline-advisers/1602181.html.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals, Inc. (NASDAQ:INO).

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.